We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Palliative Chirurgie des metastasierten Prostatakarzinoms.
- Authors
Heidenreich, Axel; Bach, Christian; Pfister, David
- Abstract
Androgen deprivation in combination with novel hormonal agents, docetaxel, or in combination with abiraterone/prednisone plus docetaxel or darolutamid plus docetaxel represent the standard therapeutic approach in metastatic hormone-sensitive prostate cancer (mHSPC). Patients with low-risk prostate cancer also benefit from additional radiation therapy or radical prostatectomy in terms of progression-free and overall survival. Despite favorable response rates, basically all patients will develop castration resistant prostate cancer (CRPC) within 2.5 to 4 years. In addition to systemic chemotherapy, second-line hormonal treatment of systemic application of radionuclides such as radium223 or 177Lu-PSMA represent salvage management options. However, nowadays about 50–65% of patients will develop symptoms due to local progression of prostate cancer which is the result of improved oncological outcomes with significantly prolonged survival times due to the new medical treatment options. Management of such symptomatic local progression will become more important in upcoming years so that all uro-oncologists need to be aware of the various surgical management options. Complications of the lower urogenital tract such as recurrent gross hematuria ± bladder clotting and with the necessity for red blood cell transfusions, subvesical obstruction and acute urinary retention, rectourethral or rectovesical fistulas might be managed by palliative surgery such as palliative transurethral resection of the prostate (TURP), radical cystectomy, radical cystoprostatectomy with urinary diversion, and pelvic exenteration. Symptomatic or asymptomatic obstruction of the upper urinary tract might be managed by endoluminal or percutaneous urinary diversion, ureteral reimplantation, ileal ureter replacement, or implantation of the Detour® system (Coloplast GmbH, Hamburg, Germany).
- Subjects
CASTRATION-resistant prostate cancer; RED blood cell transfusion; RADIOTHERAPY; RADICAL prostatectomy; TREATMENT effectiveness; HEMATURIA; RADIOISOTOPES; METASTASIS; CANCER chemotherapy; RETENTION of urine; TRANSURETHRAL prostatectomy
- Publication
Die Urologie, 2024, Vol 63, Issue 3, p241
- ISSN
2731-7064
- Publication type
Article
- DOI
10.1007/s00120-024-02285-8